Clinical Trial Search

Primary: Median Percent Change From Baseline in All Partial Seizure Frequency (Complex Partial Seizures (CP)+ Simple Partial Seizures (SP) + Secondary Generalization Seizures…

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 15.9; 28.0; 30.7 percentage of participants — p=0.0062

Primary: Progression-Free Survival (PFS) as Assessed by the Investigator — 10.2; 8.8 Months

Primary: Time to Progression of Disease — 12.6; 9.9 Months — p=0.196

Primary: Change From Baseline in Total Nasal Symptom Score (TNSS) Assessed by the Investigator at Week 2 — -1.96; -1.94; -1.87 Score on a Scale — p=0.661

Primary: Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots — 0; 0; 0; 0 Participants

Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…

Primary: Overall Survival (Percentage of Participants Alive) — 64.3; 70.3 percentage of patients — p=0.180

Primary: Treatment Failure — 29; 28 Percentage of participants

Primary: Duration of Overall Survival - Percentage of Participants With an Event — 72.2; 77.4 percentage of participants

Primary: The Proportion of Patients in Each Treatment Group Who Are Responders at Week 2 and Continue to be Responders at Week 5 — 57; 46 participants

Primary: the Relative Increase in Meal-induced Total GLP-1 Secretion — 2591; 3959 pM x 120 min

Primary: Overall Survival — 69.6; 59.3 months — p=0.528

Primary: Improvement of Anemia at Week 4 Assessed as Change From Baseline in Hemoglobin — 0.40 g/dL

Primary: The Percent Change From the Combined Baseline (4-week Retrospective Baseline and 4-week Prospective Baseline) in the Generalized Tonic-clonic Seizure Frequency Per Week…